M&A Deal Summary |
|
---|---|
Date | 2012-10-04 |
Target | ANI Pharmaceuticals |
Sector | Life Science |
Buyer(s) | ANI Pharmaceuticals |
Deal Type | Merger |
Advisor(s) | SNR Denton LLP (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2001 |
Sector | Life Science |
Employees | 642 |
Revenue | 487M USD (2023) |
ANI Pharmaceuticals is a developer, manufacturer, and marketer of top-quality prescription pharmaceuticals. In two facilities with combined manufacturing, packaging, and laboratory capacity exceeding 170,000 sq. ft., ANI develops and manufactures liquid, powder, and oral solid dose products, including those requiring containment. ANI also performs contract manufacturing for some of the largest and most respected pharmaceutical companies in the world. ANI has several ANDAs pending FDA approval and in various stages of development. ANI Pharmaceuticals was formed in 2001 and is based in Baudette, Minnesota.
DEAL STATS | # |
---|---|
Overall | 2 of 15 |
Sector (Life Science) | 2 of 13 |
Type (Merger) | 1 of 2 |
State (Minnesota) | 2 of 2 |
Country (United States) | 2 of 12 |
Year (2012) | 1 of 1 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2007-05-07 |
Solvay Pharmaceuticals - Rx Facilities
Baudette, Minnesota, United States Solvay Pharmaceuticals - Rx Facilities plants add 173,000 sq. ft. of manufacturing and laboratory capacity, substantially expanding capabilities and enhancing its already-rapid growth. |
Buy | - |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2013-12-26 |
Teva Pharmaceutical - 31 Generic Drug Products
United States Teva Pharmaceutical - 31 Generic Drug Products includes 20 solid-oral immediate release products, 4 extended release products and 7 liquid products. |
Buy | $13M |